Thyroid Cancer Diagnostics Market Size & Share 2024 – 2032

Thyroid Cancer Diagnostics Market Size

Thyroid Cancer Diagnostics Market size was valued at USD 2.9 billion in 2023 and is estimated to grow at 5.7% CAGR from 2024 to 2032. Thyroid cancer diagnostics encompass the processes and techniques employed by healthcare providers to identify and diagnose thyroid cancer. This includes a comprehensive assessment of medical history, physical examination, imaging tests such as ultrasound, CT scans, MRI scans, and radioiodine scans, as well as fine-needle aspiration (FNA) biopsy to analyze thyroid tissue samples for cancerous cells.

Thyroid cancer rates have been increasing worldwide due to various factors including enhanced detection methods, altered diagnostic standards, and environmental influences. Lifestyle modifications, such as dietary shifts and radiation exposure, also contribute to this trend. The American Cancer Society's 2024 estimates suggest around 44,020 new instances of thyroid cancer in the U.S., with approximately 12,500 occurring in men and 31,520 in women. Predictions also indicate roughly 2,170 fatalities due to thyroid cancer, with about 990 in men and 1,180 in women.
 

Further, thyroid cancer tends to be diagnosed at a younger age compared to other adult cancers, with the average age of diagnosis being 51 years old. With the rising number of cases, there's a growing need for improved diagnostic tools to facilitate early detection and effective treatment planning.
 

Furthermore, public health initiatives and awareness campaigns for thyroid cancer screening are pivotal in boosting early detection rates. They target high-risk populations such as those with a family history of thyroid cancer or radiation exposure. By advocating regular thyroid examinations and raising awareness about symptoms, these efforts facilitate early diagnosis, improving treatment outcomes and driving demand for diagnostic tests and services.
 

Thyroid Cancer Diagnostics Market Trends

• Recent advancements in cancer diagnostic technologies, particularly in thyroid cancer diagnostics, have brought about a transformative shift. Imaging modalities such as ultrasound, CT scanner, MRI systems, and PET scans have significantly improved the detection and characterization of thyroid nodules.
   
• Molecular diagnostics techniques such genetic mutation testing have further elevated diagnostic accuracy and prognostic capabilities.
   
• Additionally, thyroid function testing which is estimated to reach USD 6.6 billion by the end of 2032, which assess thyroid hormone and TSH levels in the blood, play a pivotal role in detecting abnormalities indicative of thyroid cancer or other thyroid gland disorders. Integrating these tests into diagnostic protocols offers a comprehensive understanding of thyroid health, empowering healthcare providers to make well-informed decisions regarding treatment strategies.
   
• These technological innovations not only enable early detection of thyroid cancer but also facilitate personalized treatment planning, ultimately enhancing diagnostic accuracy, prognostic assessment, and therapeutic outcomes in the market.
   

Thyroid Cancer Diagnostics Market Analysis

Based on product, the market is divided into instruments, and kits & consumables. The instruments segment is forecasted to reach USD 2.9 billion by 2032, showcasing robust growth propelled by several key factors.
 

• Technological advancements in diagnostic imaging technologies such as ultrasound, CT, MRI, and PET are enhancing accuracy and efficiency in thyroid cancer detection, leading to increased demand for diagnostic instruments.
   
• Moreover, the rising incidence of thyroid cancer globally, coupled with improved screening programs and better healthcare access, is necessitating the use of advanced instruments for early diagnosis and staging.
   
• The growing adoption of molecular diagnostics, fueled by the demand for precise and personalized treatment strategies, is further driving market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the thyroid cancer diagnostics market is bifurcated into papillary carcinoma, follicular carcinoma, and other types. The papillary carcinoma segment accounted for USD 2.3 billion in 2023.

• Papillary carcinoma stands out as the predominant form of thyroid cancer, making up approximately 80-85% of all cases. Its prevalence plays a crucial role in driving the market size of thyroid cancer treatments.
   
• The distinct treatment approach for papillary carcinoma necessitates specialized diagnostic tests for effective management, fostering a dedicated market for tailored diagnostics.
   
• Substantial investments in research and development have spurred the introduction of innovative technologies and tests, attracting healthcare providers and patients alike, and fueling market expansion.
   

Based on technique, the market is bifurcated into blood test, imaging, biopsy, and other techniques. The imaging segment of the thyroid cancer diagnostics market surged to USD 1.2 billion in 2023, propelled by its pivotal role in non-invasively visualizing the thyroid gland and detecting abnormalities indicative of thyroid cancer.
 

• Advanced imaging technologies, including ultrasound, CT scans, MRI scans, and nuclear medicine scans, have significantly improved accuracy and precision in identifying thyroid nodules and distinguishing between benign and malignant lesions.
   
• These techniques not only aid in initial screening and follow-up evaluations but also guide biopsy procedures for more accurate diagnosis.
   
• With the rising incidence of thyroid cancer globally, fueled by factors such as iodine deficiency and increasing awareness, the demand for imaging diagnostics is expected to continue its upward trajectory, contributing to the market's substantial growth.
   

Based on end-use, the thyroid cancer diagnostics market is bifurcated into hospitals, cancer diagnostic centers, academic and research institutes, and other end-users. The hospitals segment accounted for USD 1.2 billion in 2023.
 

• This dominance stems from hospitals' pivotal role as the primary destination for individuals seeking medical care, especially for suspected thyroid cancer cases.
   
• Hospitals offer unparalleled accessibility and convenience, coupled with specialized facilities and expertise in oncology departments staffed by seasoned professionals.
   
• With comprehensive care services ranging from diagnostic tests to surgical interventions, hospitals provide a one-stop solution for thyroid cancer patients' medical needs.
   
• Additionally, their established referral networks and streamlined reimbursement processes further bolster patient influx, making hospitals the preferred choice for thyroid cancer diagnostics.
   

The U.S. thyroid cancer diagnostics market accounted for a significant revenue of USD 1.1 billion in 2023, and this trajectory is set to continue upwards.
 

• The U.S. healthcare system's robust infrastructure, including a network of well-equipped hospitals, cancer diagnostic centers, and academic institutions, facilitates widespread access to thyroid cancer diagnostics across the country.
   
• Furthermore, ongoing research and development efforts aimed at improving diagnostic methodologies and expanding treatment options for thyroid cancer are anticipated to further stimulate market growth in the coming years.
   

The thyroid cancer diagnostics market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Government initiatives aimed at improving cancer care and early detection programs contribute to the expansion of the market in the country. Healthcare policies focused on reducing cancer mortality rates and improving patient outcomes drive investment in diagnostic technologies and infrastructure.

Japan thyroid cancer diagnostics market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Increased awareness about the importance of early detection and proactive healthcare behaviors is fueling the growth of Japan's market. This heightened awareness leads to more individuals undergoing screenings, fostering a preventive healthcare culture.
   
• Education efforts, patient advocacy groups, and improved communication between healthcare providers and patients contribute to this trend, empowering individuals to take charge of their health and seek timely diagnostic tests for thyroid cancer.
   

The thyroid cancer diagnostics market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The increasing population and healthcare expenditure in Saudi Arabia, combined with a growing demand for advanced diagnostic technologies in thyroid cancer and other cancers, are expected to stimulate significant growth in the market in the country. This upward trend underscores the recognition of the crucial importance of early and accurate diagnosis in effectively combating thyroid cancer.
   

Thyroid Cancer Diagnostics Market Share

The thyroid cancer diagnostics sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Thyroid Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the thyroid cancer diagnostics industry include:

• Abbott Laboratories
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Canon Inc.
• Danaher Corporation
• Esaote SPA
• F. Hoffmann-La Roche Ltd
• GE HealthCare
• Hologic, Inc.
• Illumina, Inc.
• Koninklijke Philips N.V.
• PerkinElmer, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Veracyte, Inc.
   

Thyroid Cancer Diagnostics Industry News

• In May 2024, GE Healthcare has introduced Revolution RT, a novel radiation therapy computed tomography (CT) solution designed to enhance imaging accuracy and streamline simulation workflow for a more personalized oncology care experience for clinicians and patients. This product launch is expected to give GE Healthcare a competitive advantage in the field of medical imaging.
   

The thyroid cancer diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
• Kits & consumables

Market, Type

• Papillary carcinoma
• Follicular carcinoma
• Other types

Market, By Technique

• Blood test
• Imaging
• Biopsy
• Other techniques

Market, By End-use

• Hospitals
• Cancer diagnostic centers
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacifi 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa